ArticleAnnals of hematology2025

Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients : Article type: research.

Yuhong Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.